🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05332756
Recruiting Observational

Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)

NCT05332756 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Observational
Started
2022-05-01
Last updated
2024-12-19

Condition(s) studied

Moyamoya Disease

Investigational drug(s) / intervention(s)

Conservative management

Conservative management: Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.

Study summary

The purpose of this study is to investigate the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives, and provide potential pathogenesis of moyamoya disease.

Eligibility

Sex
ALL
Min age
2 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients with age between 2-60 years; 2. A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease. 3. Patients are medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation. 4. Capable of understanding the purpose and risk of the study and has signed the informed consent. If the participant is not capable of this at the time of enrollment, a legally authorized representative will provide written informed consent in accordance with all regulations. 5. Ability to comply with study follow-up. Exclusion Criteria: 1. Concomitant other diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy. 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement. 3. Patients are allergic to the contrast agents. 4. Patients are treated with direct, indirect, or combined revascularization depending on the presentation. 5. Physical or subjective failure to cooperate with the examination or serious comorbid diseases. 6. Patients are unable or unlikely to return for follow-up visits. 7. Any other reasons that, in the opinion of the investigators, make the participant unsuitable for enrollment.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Capital Medical University Beijing Beijing Municipality Recruiting

More Beijing Tiantan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05332756 on ClinicalTrials.gov ↗ ← All trials in China